News
14.07.2022
PMA Insights: Week 28

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
13.07.2022
Big pharmas lose out in Chinas latest round of dru

AZ has warned its China revenues will decline mid-single-digit percentage in 2022 after years of dou...

Read more
Insider Insights
13.07.2022
NICE expands access of Tremfya in England and Wale

The HTA initially recommended Tremfya as a treatment option for adults with active psoriatic arthrit...

Read more
Articles
28.06.2022
EU Joint HTA: How will EUNetHTA balance contrastin...

The EUNetHTA recently published its draft scoping guidance which outlines how the contrasting decisi...

Read more
Insider Insights
27.06.2022
EURORDIS release joint statement on patient access

They came up with six proposals, split into three subgroups, aimed at addressing the key barriers to...

Read more
Insider Insights
23.06.2022
NICE publish their new real world evidence framewo

NICE have been clear that this framework should not be interpreted as minimum standards for real-wor...

Read more
Insider Insights
23.06.2022
AIFA reorganisation delayed again

It is widely expected that the reform will entail the unification of the CTS and the CPR into one bo...

Read more
Articles
22.06.2022
EU Joint HTA: How should manufacturers adapt to th...

EUnetHTA and the EU Joint HTA Process EUnetHTA was established in 2006 to facilitate information sha...

Read more
Articles
21.06.2022
Seeking early advice from the EMA and multiple HTA...

Introduction Achieving access to patients for innovative treatments is becoming a significant challe...

Read more
Insider Insights
20.06.2022
NICE trials new proportionate approach to increase

The aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.